

LAB #: F000000-0000-0 **PATIENT: Sample Patient**

ID: P000000000 **SEX: Female**

DOB: **AGE: 88** **CLIENT #: 12345** DOCTOR:

Doctor's Data, Inc. 3755 Illinois Ave.

St. Charles, IL 60174 U.S.A.

Microbiology Profile, stool

BACTERIOLOGY CULTURE

Commensal (Imbalanced) flora

2+ Alpha hemolytic strep

1+ Gamma hemolytic strep

Dysbiotic flora

4+ Klebsiella pneumoniae ssp pneumoniae

4+ Escherichia coli

1+ Lactobacillus spp.

NG Bifidobacterium spp.

Expected/Beneficial flora

4+ Bacteroides fragilis group

1+ Enterococcus spp.

3+ Clostridium spp.

NG = No Growth

BACTERIA INFORMATION

Expected /Beneficial bacteria make up a significant portion of the total microflora in a healthy & balanced GI tract. These beneficial bacteria have many health-protecting effects in the GI tract including manufacturing vitamins, fermenting fibers, digesting proteins and carbohydrates, and propagating antitumor and anti-inflammatory factors.

Clostridia are prevalent flora in a healthy intestine. Clostridium spp. should be considered in the context of balance with other expected/beneficial flora. Absence of clostridia or over abundance relative to other expected/beneficial flora indicates bacterial imbalance. If C. difficile associated disease is suspected, a Comprehensive Clostridium culture or toxigenic C. difficile DNA test is recommended.

Commensal (Imbalanced) bacteria are usually neither pathogenic nor beneficial to the host GI tract. Imbalances can occur when there are insufficient levels of beneficial bacteria and increased levels of commensal bacteria. Certain commensal bacteria are reported as dysbiotic at higher levels.

Dysbiotic bacteria consist of known pathogenic bacteria and those that have the potential to cause disease in the GI tract. They can be present due to a number of factors including: consumption of contaminated water or food, exposure to chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

YEAST CULTURE

Normal flora

Dysbiotic flora

No yeast isolated

MICROSCOPIC YEAST

Result:

Expected:

Mod

None - Rare

Yeast in stool is expected at a level of nonerare. A microscopic finding of yeast in stool of few, moderate, or many may be helpful in identifying potential yeast overgrowth, or nonviable or dietary yeast.

YEAST INFORMATION

Yeast may normally be present in small quantities in the skin, mouth, and intestine. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast are not uniformly dispersed throughout the stool and this may lead to undetectable or low levels of yeast identified by microscopy, despite culture and identified yeast species. Conversely, microscopic examination may reveal a significant amount of yeast present but no viable yeast cultured. Yeast may not always survive transit through the intestines. Nonviable dietderived yeast may also be detected microscopically. Consideration of clinical intervention for yeast detected microscopically should be made in the context of other findings and presentation of symptoms.

Comments:

Date Collected: 08/14/2017 Date Received: 08/17/2017 Date Reported: 08/24/2017

* Aeromonas, Campylobacter, Plesiomonas, Salmonella, Shigella, Vibrio, Yersinia, & Edwardsiella tarda have been specifically tested for and found absent unless

reported.






LAB #: F000000-0000-0
PATIENT: Sample Patient

ID: P0000000000 SEX: Female AGE: 88 CLIENT #: 12345 DOCTOR:

Doctor's Data, Inc. 3755 Illinois Ave.

St. Charles, IL 60174 U.S.A.

Bacterial Susceptibilities: Klebsiella pneumoniae ssp pneumoniae



Natural antibacterial agents may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative sensitivity is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative sensitivity is defined for the natural agents tested.

PRESCRIPTIVE AGENTS				
	Resistant	Intermediate	Susceptible	Susceptible results imply that an infection
Amoxicillin-Clavulanic Acid			S	due to the bacteria may be appropriately treated when the recommended dosage of
Ampicillin	R			the tested antimicrobial agent is used. Intermediate results imply that response
Cefazolin			s	rates may be lower than for susceptible bacteria when the tested antimicrobial
Ceftazidime			s	agent is used.
Ciprofloxacin			S	Resistant results imply that the bacteria will not be inhibited by normal dosage levels of
Trimeth-sulfa			S	the tested antimicrobial agent.

Comments:

Date Collected: 08/14/2017
Date Received: 08/17/2017
Date Completed: 08/24/2017

Natural antibacterial agent susceptibility testing is intended for research use only.

Not for use in diagnostic procedures.

v10.11

Microbiology Profile

Lab number: **F000000-0000-0** Page: 1 Patient: Sample Patient Client: 12345

INTRODUCTION

This analysis of the stool specimen provides fundamental information about the overall gastrointestinal health of the patient. When abnormal microflora or significant aberrations in intestinal health markers are detected, specific interpretive paragraphs are presented. If no significant abnormalities are found, interpretive paragraphs are not presented.

Clostridium spp

Clostridia are expected inhabitants of the human intestine. Although most clostridia in the intestine are not virulent, certain species have been associated with disease. Clostridium perfringens is a major cause of food poisoning and is also one cause of antibioticassociated diarrhea. Clostridium difficile is a causative agent in antibiotic-associated diarrhea and pseudomembranous colitis. Other species reported to be prevalent in high amounts in patients with Autistic Spectrum Disorder include Clostridium histolyticum group, Clostridium cluster I, Clostridium bolteae, and Clostridium tetani.

If these disease associations are a concern further testing may be necessary.

Washington W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, Woods, G. Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th edition. Lippincott Williams and Wilkins; 2006. pg 931-939

Song Y, Liu C, Finegold SM. Real-Time PCR Quantitation of Clostridia in Feces of Autistic Children. Applied and Environmental Microbiology. Nov. 2004, 6459-6465.

Parracho H, Bingham MO, Gibson GR, McCartney AL. Differences Between the Gut Microflora of Children with Autistic Spectrum Disorders and That of Healthy Children. Journal of Medical Microbiology, 2005:54, 987-991.

Imbalanced flora

Imbalanced flora are those bacteria that reside in the host gastrointestinal tract and neither injure nor benefit the host. Certain dysbiotic bacteria may appear under the imbalances category if found at low levels because they are not likely pathogenic at the levels detected. When imbalanced flora appear, it is not uncommon to find inadequate levels of one or more of the beneficial bacteria and/or a fecal pH which is more towards the alkaline end of the reference range (6 - 7.8). It is also not uncommon to find hemolytic or mucoid E. coli with a concomitant deficiency of beneficial E. coli and alkaline pH, secondary to a mutation of beneficial E. coli in alkaline conditions (DDI observations). Treatment with antimicrobial agents is unnecessary unless bacteria appear under the dysbiotic category.

Microbiology Profile

Lab number: **F000000-0000-0** Page: 2 Patient: Sample Patient Client: 12345

Mackowiak PA. The normal microbial flora. N Engl J Med. 1982;307(2):83-93.

Dysbiotic Flora

In a healthy balanced state of intestinal flora, the beneficial bacteria make up a significant proportion of the total microflora. However, in many individuals there is an imbalance or deficiency of beneficial flora and an overgrowth of non-beneficial (imbalance) or even pathogenic microorganisms (dysbiosis). This can be due to a number of factors including: consumption of contaminated water or food; daily exposure of chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

A number of toxic substances can be produced by the dysbiotic bacteria including amines, ammonia, hydrogen sulfide, phenols, and secondary bile acids which may cause inflammation or damage to the brush border of the intestinal lining. If left unchecked, long-term damage to the intestinal lining may result in leaky gut syndrome, allergies, autoimmune disease (e.g. rheumatoid arthritis), irritable bowel syndrome, fatigue, chronic headaches, and sensitivities to a variety of foods. In addition, pathogenic bacteria can cause acute symptoms such as abdominal pain, nausea, diarrhea, vomiting, and fever in cases of food poisoning.

Bacterial sensitivities to a variety of prescriptive and natural agents have been provided for the pathogenic bacteria that were cultured from this patient's specimen. This provides the practitioner with useful information to help plan an appropriate treatment regimen. Supplementation with probiotics or consumption of foods (yogurt, kefir, miso, tempeh, tamari sauce) containing strains of lactobacilli, bifidobacteria, and enterococci can help restore healthy flora levels. Polyphenols in green and ginseng tea have been found to increase the numbers of beneficial bacteria. Hypochlorhydria may also predispose an individual to bacterial overgrowth, particularly in the small intestine. Nutritional anti-inflammatories can aid in reversing irritation to the GI lining. These include guercetin, vitamin C, curcumin, gamma-linoleic acid, omega-3 fatty acids (EPA, DHA), and aloe vera. Other nutrients such as zinc, beta-carotene, pantothenic acid, and L-glutamine provide support for regeneration of the GI mucosa. A comprehensive program may be helpful in individuals in whom a dysbiotic condition has caused extensive GI damage.

Lispki E. Digestive Wellness. New Canaan, CT: Keats Publishing; 1996.

Mitsuoka T. Intestinal Flora and Aging. Nutr Rev 1992;50(12):438-446.

Weisburger JH. Tea and Health: The Underlying Mechanisms. Proc Soc Exp Biol Med 1999;220(4):271-275.4.

Pereira SP, Gainsborough N, Dowling RH. Drug-induced Hypochlorhydria Causes High Duodenal Bacterial Counts in the Elderly. Ailment Pharmacol Ther 1998;12(1)99-104.

Murray MT. Stomach Ailments and Digestive Disturbances. Rocklin, CA: Prima Publishing; 1997.

Microbiology Profile

Page: 3

Client: 12345

Lab number: F000000-0000-0 Patient: Sample Patient

Klebsiella species

Klebsiella belongs to the Enterobacteriaceae family and is closely related to the genera Enterobacter and Serratia. This gram-negative bacterium is considered dysbiotic in the amount of 3 - 4+.

Klebsiellae are widely distributed in nature and in the gastrointestinal tract of humans. In humans, they may colonize the skin, oral cavity, pharynx, or gastrointestinal tract. Klebsiellae may be regarded as normal flora in many parts of the colon, intestinal tract and biliary tract, but the gut is also the main reservoir of opportunistic strains.

This bacterium has the potential to cause intestinal, lung, urinary tract, and wound infections in susceptible individuals, but Klebsiella overgrowth is commonly asymptomatic. K. pneumoniae, in particular, may cause diarrhea and some strains are enterotoxigenic. Infection has been linked to ankylosing spondylitis as well as myasthenia gravis (antigenic cross-reactivity), and these patients usually carry larger numbers of the organism in their intestines than healthy individuals. Klebsiella oxytoca has been found to be the cause of antibiotic-associated hemorrhagic colitis. These strains have been shown to produce a cytotoxin that is capable of inducing cell death in various epithelialcell cultures.

Klebsiella is also an infamously known nosocomial infectious agent, partially due to the ability of organisms to spread rapidly. Klebsiella accounts for approximately 3-7% of all hospital-acquired infections, placing it among the top eight pathogens in hospitals. Extraintestinal infection typically involves the respiratory or urinary tracts, but may infect other areas such as the biliary tract and surgical wound sites. K. pneumoniae and K. oxytoca are the two members of this genus responsible for most extraintestinal human infections.

Treatment of these species has become a major problem in most hospitals because of resistance to multiple antibiotics and potential transfer of plasmids to other organisms. Proper hand washing is crucial to prevent transmission from patient to patient via medical personnel. Contact isolation should be used for patients colonized or infected with highly antibiotic-resistant Klebsiella strains.

Klebsiella ozaenae and Klebsiella rhinoscleromatis are infrequent isolates that are subspecies of K. pneumoniae; however, each is associated with at unique spectrum of disease. K. ozaenae is associated with atrophic rhinitis, a condition called ozena, and purulent infections of the nasal mucous membranes. K. rhinoscleromatis causes the granulomatous disease rhinoscleroma, an infection of the respiratory mucosa, oropharynx, nose, and paranasal sinuses.

For the otherwise healthy individual, antimicrobial therapy is often unnecessary. Klebsiella thrives on a diet high in starch, so a low-starch diet may be helpful. A further caution is that Klebsiella thrives on Fructooligosaccharides (FOS) a class of oligosaccharides used as an artificial or alternative sweetener. Antibiotics may be indicated if symptoms are prolonged and in systemic infections. Refer to the bacterial sensitivities to identify the most appropriate pharmaceutical or natural agent.

Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a Causative Organism of Antibiotic-Associated Hemorrhagic Colitis. New England Journal of Medicine. December 2006;355;23.

Lab number: F000000-0000-0 Microbiology Profile Page: 4
Patient: Sample Patient Client: 12345

Levy I et al. Nosocomial Infections After Cardiac Surgery in Infants and Children: Incidence and Risk Factors. J Hosp Infect. 2003;53(2):111-6.

Washington W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, Woods, G. Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th edition. Lippincott Williams and Wilkins; 2006. pg 259-264.

Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Manual of Clinical Microbiology, 8th edition. Washington, DC: ASM Press; 2003. pg 688-689.

Microscopic yeast

Microscopic examination has revealed yeast in this stool sample. The microscopic finding of yeast in the stool is helpful in identifying whether the proliferation of fungi, such as Candida albicans, is present. Yeast is normally found in very small amounts in a healthy intestinal tract. While small quantities of yeast (reported as none or rare) may be normal, yeast observed in higher amounts (few, moderate to many) is considered abnormal.

An overgrowth of intestinal yeast is prohibited by beneficial flora, intestinal immune defense (secretory IgA), and intestinal pH. Beneficial bacteria, such as Lactobacillus colonize in the intestines and create an environment unsuitable for yeast by producing acids, such as lactic acid, which lowers intestinal pH. Also, lactobacillus is capable of releasing antagonistic substances such as hydrogen peroxide, lactocidin, lactobacillin, and acidolin.

Many factors can lead to an overgrowth of yeast including frequent use of antibiotics (leading to insufficient beneficial bacteria), synthetic corticosteroids, oral contraceptives, and diets high in sugar. Although there is a wide range of symptoms which can result from intestinal yeast overgrowth, some of the most common include brain fog, fatigue, reccurring vaginal or bladder infections, sensitivity to smells (perfumes, chemicals, environment), mood swings/depression, sugar and carbohydrate cravings, gas/bloating, and constipation or loose stools.

A positive yeast culture (mycology) and sensitivity to prescriptive and natural agents is helpful in determining which anti-fungal agents to use as part of a therapeutic treatment plan for chronic colonic yeast. However, yeast are colonizers and do not appear to be dispersed uniformly throughout the stool. Yeast may therefore be observed microscopically, but not grow out on culture even when collected from the same bowel movement.

Beneficial Flora

One or more of the expected or beneficial bacteria are low in this specimen. Normally abundant include lactobacilli, bifidobacteria, clostridia, Bacteroides fragilis group, enterococci, and some strains of Escherichia coli. The beneficial flora have many health-protecting effects in

Lab number: F000000-0000-0 Microbiology Profile
Patient: Sample Patient

Page: 5

Client: 12345

the gut, and as a consequence, are crucial to the health of the whole organism. Some of the roles of the beneficial flora include digestion of proteins and carbohydrates, manufacture of vitamins and essential fatty acids, increase in the number of immune system cells, break down of bacterial toxins and the conversion of flavinoids into anti-tumor and anti-inflammatory factors. Lactobacilli, bifidobacteria, clostridia, and enterococci secrete lactic acid as well as other acids including acetate, propionate, butyrate, and valerate. This secretion causes a subsequent decrease in intestinal pH, which is crucial in preventing an enteric proliferation of microbial pathogens, including bacteria and yeast. Many GI pathogens thrive in alkaline environments. Lactobacilli also secrete the antifungal and antimicrobial agents lactocidin, lactobacillin, acidolin, and hydrogen peroxide. The beneficial flora of the GI have thus been found useful in the inhibition of microbial pathogens, prevention and treatment of antibiotic associated diarrhea, prevention of traveler's diarrhea, enhancement of immune function, and inhibition of the proliferation of yeast.

In a healthy balanced state of intestinal flora, the beneficial flora make up a significant proportion of the total microflora. Healthy levels of each of the beneficial bacteria are indicated by either a 3+ or 4+ (0 to 4 scale). However, some individuals have low levels of beneficial bacteria and an overgrowth of nonbeneficial (imbalances) or even pathogenic microorganisms (dysbiosis). Often attributed to the use of antibiotics, individuals with low beneficial bacteria may present with chronic symptoms such as irregular transit time, irritable bowel syndrome, bloating, gas, chronic fatigue, headaches, autoimmune diseases (e.g., rheumatoid arthritis), and sensitivities to a variety of foods. Treatment may include the use of probiotic supplements containing various strains of lactobacillus and bifidobacterium species and consumption of cultured or fermented foods including yogurt, kefir, miso, tempeh and tamari sauce. Polyphenols in green and ginseng tea have been found to increase the numbers of beneficial bacteria. If dysbiosis is present, treatment may also include the removal of pathogenic bacteria, yeast, or parasites.

Percival M. Intestinal Health. Clin Nutr In. 1997;5(5):1-6.

Fuller R. Probiotics in Human Medicine. Gut. 1991:32: 439-442.

Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacilli GG Yoghurt in Prevention of Antibiotic Associated Diarrhea. Ann Med. 1990; 22:57-59.

Oksanen P, Salminen S, Saxelin M, et al. Prevention of Travelers' Diarrhea by Lactobacillus GG. Ann Med. 1990; 22:53-56.

Perdigon G, Alvarez M, et al. The Oral Administration of Lactic Acid Bacteria Increases the Mucosal Intestinal Immunity in Response to Enteropathogens. J Food Prot. 1990;53:404-410.

Valeur, N, et al. Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal Tract. Appl Environ. Microbiol. 2004 Feb; 70(2):1176-81.

Elmer G, Surawicz C, and McFarland L. Biotherapeutic agents - a Neglected Modality for the Treatment and Prevention of Intestinal and Vaginal Infections. JAMA. 1996; 275(11):870-876.

Fitzsimmons N and Berry D. Inhibition of Candida albicans by Lactobacillus acidophilus: Evidence for Involvement of a Peroxidase System. Microbio. 1994; 80:125-133

© 1999-2017 Doctor's Data, Inc.

Lab number: **F000000-0000-0** Patient: **Sample Patient**

Microbiology Profile

Page: 6 Client: **12345**

Weisburger JH. Proc Soc Exp Biol Med 1999;220(4):271-5.